Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis

被引:11
作者
Abdel-Rahman, Omar [1 ,2 ]
机构
[1] Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada
[2] Ain Shams Univ, Fac Med, Clin Oncol Dept, Cairo, Egypt
关键词
Lung cancer; Women; HRT; PLCO trial; Incidence; Mortality; RISK; ESTROGEN; HEALTH;
D O I
10.1007/s10147-020-01615-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To evaluate the impact of hormone replacement therapy (HRT) on the incidence and mortality of lung cancer among female participants in the prostate, lung, colorectal, and ovary (PLCO) trial. Methods All women participating in the PLCO trial with complete information about HRT exposure were included in the current analysis. All study population were aged 55-74 years without prior history of lung cancer at the time of study enrollment. Multivariate Cox regression analysis was used to evaluate the impact of HRT exposure on lung cancer incidence and mortality. For both end points, the model was adjusted for: age, body mass index, study arm, race, cigarette smoking and family history of lung cancer. Results A total of 77,911 female participants were included in the current analysis, including 27,663 participants who never used HRT before inclusion into the PLCO trial and 50,248 participants who used some form of HRT before inclusion into the PLCO trial. Prior exposure to HRT seems to be protective against the development of lung cancer in a multivariate analysis (hazard ratio for ever exposure versus never exposure 0.876; 95% CI 0.783-0.981; P = 0.022). Similarly, prior exposure to HRT seems also to be protective against death from lung cancer in a multivariate analysis (hazard ratio for ever exposure versus never exposure 0.814; 0.709-0.934; P = 0.003). Further multivariate Cox regression analysis showed that current HRT usage at the time of PLCO trial entry (and not former HRT usage) seemed to be protective against lung cancer development (hazard ratio for current versus never users 0.842; 0.743-0.954; P = 0.007) and lung cancer-specific mortality (hazard ratio for current versus never users 0.800; 0.686-0.932; P = 0.004). Conclusion HRT use at the time of PLCO trial entry seems to be associated with lower probability of lung cancer development and death. Further studies are needed to elucidate the biological mechanisms behind this observation.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 20 条
[4]   Estrogen and colon cancer: current issues [J].
Al-Azzawi, F ;
Wahab, M .
CLIMACTERIC, 2002, 5 (01) :3-14
[5]  
Bae Jong-Myon, 2015, J Prev Med Public Health, V48, P280, DOI 10.3961/jpmph.15.054
[6]   Reproductive and Hormonal Factors and Lung Cancer Risk in the NIH-AARP Diet and Health Study Cohort [J].
Brinton, Louise A. ;
Gierach, Gretchen L. ;
Andaya, Abegail ;
Park, Yikyung ;
Schatzkin, Arthur ;
Hollenbeck, Albert R. ;
Spitz, Margaret R. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (05) :900-911
[7]  
Brood-van Zanten MMA, 2002, MATURITAS, V43, pS57
[8]   Breast cancer risk with postmenopausal hormonal treatment [J].
Collins, JA ;
Blake, JM ;
Crosignani, PG .
HUMAN REPRODUCTION UPDATE, 2005, 11 (06) :545-560
[9]   Reduced mortality associated with long-term postmenopausal estrogen therapy [J].
Ettinger, B ;
Friedman, GD ;
Bush, T ;
Quesenberry, CP .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (01) :6-12
[10]   Hormone therapy and lung cancer mortality in women: Systematic review and meta-analysis [J].
Li, Wentao ;
Lin, Xiaona ;
Wang, Rui ;
Wang, Feng ;
Xie, Shaohua ;
Tse, Lap Ah .
STEROIDS, 2017, 118 :47-54